Your search found 1 Results
[Pharmaceutical and economic aspects of high blood pressure treatment in Morocco] Aspects pharmaco-économiques du traitement de l’hypertension artérielle au Maroc.
Espérance Médicale. 2002 Oct; 9(87):540-544.In this article, the authors try to evaluate the scope of under-medication in the case of high blood pressure (HBP) in Morocco, and they attempt to evaluate certain pharmaceutical economic aspects of high blood pressure medication by utilizing the various data in the subject, as presented in tables. Analyses of these data showed the following elements: consumption of high blood pressure medication in Morocco remains quite low in comparison with the theoretical needs of the population, the consumption/need ratio, especially in private/pharmacy consumption corresponds to 2.3% of the needs of the population in HBP medication, a price analysis shows a sizeable variation in these values both between different families of high blood pressure medication and within a single family. The economic factor seems to be the primary obstacle to this consumption. An analysis of monthly costs for HBP treatment shows that they are relatively high, and represent on average, 11% of the Moroccan minimum wage. This chronic condition remains quite common, it affects a third of the adult Moroccan population. And despite the encouraging medical context, care of a hypertensive subject in Morocco remains unsatisfactory, all the more so given that generic antihypertensives remain modest in comparison with other drug classes. Not forgetting the absence of coverage by required health insurance and the relatively low purchasing power. In conclusion, the figures presented do not constitute an accurate image of the reality of consumption of these drugs in Morocco, but represent good indicators in order to allow this consumption to be monitored over several years.